Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Anti-CD3 anti-EpCAM bispecific antibody, MT110 monoclonal antibody, Solitomab + [3] |
Target |
Action stimulants, modulators |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), EpCAM modulators(Epithelial cell adhesion molecule modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Solitumomab | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of Lung | Phase 1 | Germany | 01 Mar 2008 | |
Breast Cancer | Phase 1 | Germany | 01 Mar 2008 | |
Castration-Resistant Prostatic Cancer | Phase 1 | Germany | 01 Mar 2008 | |
Colorectal Cancer | Phase 1 | Germany | 01 Mar 2008 | |
Gastroesophageal junction adenocarcinoma | Phase 1 | Germany | 01 Mar 2008 | |
Ovarian Cancer | Phase 1 | Germany | 01 Mar 2008 | |
Small Cell Lung Cancer | Phase 1 | Germany | 01 Mar 2008 |
Phase 1 | 65 | coykwebrtl(kakztircqx) = Fifteen patients had dose-limiting toxicities (DLTs): eight had transient abnormal liver parameters shortly; one had supraventricular tachycardia (grade 3); Six patients had a DLT of diarrhea ebcvczwaie (oxkrfjueyu ) View more | Negative | 18 Apr 2018 | |||
Not Applicable | - | (T regulatory cells) | qtxdajvbjv(ejczetotat) = blwoajkhqf mkudgnzawx (ktdvbsqlio ) | - | 15 Apr 2012 |